On August 20, 2020, the United States Drug Enforcement Administration (“DEA”) issued an interim final rule (“IFR”) pertaining to the classifications of marijuana and hemp under the federal Controlled Substances Act (“CSA”) in light of the 2018 Agricultural Improvement Act (“AIA”). Because the DEA … Read more about Is the DEA Coming for the Hemp Industry After All?
On Monday, April 6, GW Pharmaceuticals revealed that the company had received notice from the U.S. Drug Enforcement Administration (“DEA”) stating that its drug Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”). In a company release announcing the agency … Read more about DEA Removes CBD from Controlled Substances Act
Securing federal trademark protection for products derived from industrial hemp has proven to be a challenge for many in the industry. The United States Patent and Trademark Office (the “USPTO) categorically denies any trademark application that is submitted for an “illegal” product or service.1 Up … Read more about The Agricultural Improvement Act of 2018 & Federal Trademarks
An official policy change at Los Angeles International Airport (LAX) allows passengers traveling through the airport with marijuana, in accordance with California’s marijuana regulations, to avoid arrest, at least by the airport’s police officers. The policy change is just now getting media … Read more about LAX Allows Travelers to Keep Cannabis
The Drug Enforcement Administration (DEA) has rescheduled the cannabidiol (CBD) based drug Epidolex, but limited the rescheduling to exclude all CBD products. Epidiolex will be scheduled at Schedule 5, the lowest level of drug scheduling under the Controlled Substances Act (CSA). Epidiolex, … Read more about DEA Reschedules CBD-Based Epidiolex